BioNTech changed the manufacturing process after providing a peak at BNT211 during last year’s ESMO Congress. The new data cut features a more automated manufacturing process that is more robust ...

At the ESMO congress, the German biotech reported ... "This new dataset further supports the encouraging results we have seen for BNT211 to date," commented Prof Özlem Türeci, BioNTech's chief ...

At the ESMO Congress 2023 in Madrid ... Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “BNT211 aims to address two of the key limitations of CAR-T cell approaches ...

At ESMO, the mRNA specialist reported updated ... as well as infiltrate and survive in the hostile microenvironment of the tumour. “BNT211 aims to address two of the key limitations of CAR ...

The data were presented in the Investigational Immunotherapy Proffered Paper Session at the European Society for Medical Oncology (ESMO ... results we have seen for BNT211 to date.

“This year’s ESMO presentations underline the potential ... autologous Claudin-6 (CLDN6)-directed CAR-T cell therapy BNT211 (NCT04503278), including data showing the potential of combining ...

and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (“CARVac”) Data presented at ESMO Congress 2023 demonstrates that the application of CARVac increases the persistence of the adoptively ...

BNT211 is a novel therapeutic approach which ... The updated data read-out presented at ESMO (data cut-offs: June 15, 2022 for safety and August 16, 2022 for efficacy) included data from 22 ...

The data were presented in the Investigational Immunotherapy Proffered Paper Session at the European Society for Medical Oncology (ESMO) Congress 2022 by Prof. Andreas Mackensen, M.D., University ...